Last Updated 2 October 2014
The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. The prevalence of COPD increases as populations age, which is coupled with an increasing diagnosis rate as efforts to promote awareness of the disease continue and the use of spirometry to diagnose COPD becomes more widespread. This expanding COPD patient population has great unmet need because truly disease-modifying pharmacotherapies are lacking; current treatment is dominated by bronchodilators that help alleviate symptoms but do not reverse the progression of COPD. However, polypharmacy is common and therapies that offer incremental improvements over existing treatment modalities will garner use as they alleviate some of the burden associated with pharmacotherapy. Major-market COPD sales will grow substantially over our forecast period owing to the uptake of once-daily, fixed-dose combinations and the increasing drug-treated population.